Eli Lilly reports strongest weight-loss data yet; Sanofi and Regeneron secure $1 billion upfront deal
The weekly Endpoints newsletter dated October 3, 2026 highlights that Eli Lilly's latest weight‑loss trial produced its best‑ever results.
While the article does not provide specific numbers, the data are described as an improvement over previous studies, indicating a positive readout for the program.
At the same time, Sanofi and Regeneron announced a renewed collaboration that includes a $1 billion upfront payment, reflecting strong confidence in their joint pipeline.
The piece is part of the Endpoints Weekly series and encourages readers to subscribe for full access to articles and newsletters.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Eli Lilly’s best-ever weight loss data; Sanofi, Regeneron re-up for $1B upfront; and more”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that